medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2014, Número 02

<< Anterior Siguiente >>

Ginecol Obstet Mex 2014; 82 (02)


Guía de práctica clínica para el diagnóstico y tratamiento de la hiperprolactinemia

Salazar-López-Ortiz CG, Hernández-Bueno JA, González-Bárcena D, López-Gamboa M, Ortiz-Plata A, Porias-Cuéllar HL, Rembao-Bojórquez JD, Sandoval-Huerta GA, Tapia-Serrano R, Vázquez-Castillo GG, Vital-Reyes VS

Idioma: Español
Referencias bibliográficas: 64
Paginas: 123-142
Archivo PDF: 896.33 Kb.


RESUMEN

Antecedentes: la hiperprolactinemia es un hallazgo frecuente en la práctica clínica diaria de endocrinólogos, ginecólogos, médicos generales y otros. Todos deben conocer las indicaciones y parámetros de la determinación de prolactina sérica para establecer el diagnóstico de hiperprolactinemia y enviar al paciente a la correcta valoración o iniciar el tratamiento.
Objetivo: formular una guía de práctica clínica basada en evidencia para el diagnóstico y tratamiento de la hiperprolactinemia.
Método: ensayo transversal y retrospectivo basado en la búsqueda de la evidencia más sólida disponible en el momento de su desarrollo y en el análisis de guías de diagnóstico y tratamiento estandarizadas para población adolescente y adulta con diagnóstico de hiperprolactinemia. En la búsqueda, selección y análisis de la bibliografía participaron los especialistas señalados enseguida del título de esta guía.
Resultados: se reunieron las evidencias de mayor utilidad clínica para establecer el diagnóstico oportuno de hiperprolactinemia y diseñar la mejor opción de tratamiento para cada paciente.
Conclusiones: se presentan las recomendaciones establecidas por el panel de expertos para el diagnóstico y tratamiento de pacientes con niveles de prolactina elevados; así como el nivel de evidencia para diagnosticar la hiperprolactinemia, tratar la hiperprolactinemia inducida por medicamentos y los prolactinomas en pacientes embarazadas o no embarazadas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ezzat S, Asa SL, Couldwell WT, Barr CE, et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613-61.

  2. Berinder K, Stackenäs I, Akre O, Hirschberg AL, Hulting AL. Hyperprolactinemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol (Oxf) 2005;63:450-455.

  3. Melmed S, Casanueva FF, Hoffman RA, Kleinberg LD, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011;96:273-288.

  4. Berek JS. Ginecología de Novak. 14ª ed. Madrid: Lippincott Williams & Wilkins, 2008;1141-54.

  5. Molitch ME. Prolactin. En: The pituitary. (ed. S. Melmed). Cambridge: Blackwell Sciences, 1995;136-186.

  6. Braunwald E. Harrison, principios de medicina interna. 15ª ed. México: McGraw-Hill, 2005;2536-40.

  7. Brue T, Delemer B. Diagnosis and management of hyperprolactinemia: expert consensus - French society of endocrinology. Ann Endocrinol (Paris) 2007;68:58-64.

  8. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ 2003;169:575-81.

  9. Kars M, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 2009;94:2729-2734.

  10. Casanueva FF, Molitch EM, Schlechte AJ, Abs R, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006;65:265-273.

  11. Wang AT, Mullan RJ, Lane MA, Hazem A, et al. Treatment of hyperprolactinemia: a systematic review and metaanalysis. Systematic Reviews 2012;33:1-13.

  12. Al-Shraim M, Asa SL. The 2004 World Health Organization classification of pituitary tumors: What is new? Acta Neuropathol 2006;111:1-7.

  13. Glezer AD, Bronstein DM. Approach to the patient with persistent hyperprolactinemia and negative sellar imaging. J Clin Endocrinol Metab 2012;97:2211-2216.

  14. La Torre D, Falorni A. Pharmacological causes of hyperprolactinemia. Therapeutics and Clinical Risk Management 2007;3:929-951.

  15. Srikantha M, Butterworth R. Pharmacological hyperprolactinaemia. BMJ Case Rep 2009;bcr01.2009.1432.

  16. Dekkers MO, Lagro J, Burman P, Jørgensen OJ, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2010:95;43-051.

  17. Ionescu O, Vulpoi C, Cristea C, Ionescu D, Zbranca E. Hyperprolactinemia and pregnancy. Rev Med Chir Soc Med Nat Iasi 2002;106:60-4.

  18. Prabhakar VK, Davis JR. Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol. 2008;22:341–353.

  19. Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB. Hyperprolactinemia and contraception: a prospective study. Obstet Gynaecol. 1985;65:506–510.

  20. Torres Y, Acebes JJ, Soler J. Incidentaloma hipofisario: evaluación y abordaje terapéutico en la actualidad. Endocrinol Nutr. 2003;50:153-5.

  21. Donadio F, Barbieri A, Angioni R, Mantovani G, et al. Patients with macroprolactinaemia: clinical and radiological features. Eur J Clin Invest 2007;37:552–557.

  22. Amadori P, Dilberis C, Marcolla A, Pinamonti M, et al. Macroprolactinemia: predictability on clinical basis and detection by PEG precipitation with two different immunometric methods. J Endocrinol Invest 2003;26:148–156.

  23. Hattori N. Macroprolactinemia: a new cause of hyperprolactinemia. J Pharmacol Sci 2003;92:171–177.

  24. Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf). 2006;65:524–529.

  25. Bayrak A, Saadat P, Mor E, Chong L, et al. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril 2005;84:181-184.

  26. Páramo C. Incidentalomas hipofisarios. Endocrinol Nutr. En prensa.

  27. Lucas T. Problemas en el diagnóstico diferencial de las hiperprolactinemias. Endocrinol Nutr 2004;51:241-4.

  28. Moreno B, Obiols G, Páramo C, Zugasti A. Guía clínica del manejo del prolactinoma y otros estados de hiperprolactinemia. Endocrinol Nutr 2005;52:9-17.

  29. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008;37:67-99.

  30. Montero C. Los fundamentos fisicoquímicos de la fijación formalínica. Patología 1997;35:145-51.

  31. Rosai J. Introduction. Rosai and Ackerman’s Surgical Pathology. 9th ed. London: Mosby, 2004;5-9.

  32. Rembao-Bojórquez D, Vega-Orozco R, Salinas Lara C. Neuropatología quirúrgica. Parte II. El reporte histopatológico. Arch Neurocien 2005;10:15-18.

  33. Kleinschmidt - DeMasters BK. Subtyping does matter in pituitary adenomas. Acta Neuropathol 2006;111:84-85.

  34. Osamura RY, Kajiya H, Takei M, Egashira N, et al. Pathology of the human pituitary adenomas. Histochem Cell Biol 2008:130;495-507.

  35. Asa SL. Tumors of the pituitary gland. Atlas of tumor pathology. Third series, Fascicle 22. Armed Forces Institute of Pathology, Washington, 1998.

  36. Kovacs K. The 2004 WHO classification of pituitary tumors: comments. Acta Neuropathol 2006;111:62-63.

  37. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas; results of a prospective multicenter study. J. Clin Endocrinol Metab 1985;60:698-705.

  38. Dos Santos Nunes VD, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia. A systematic review of randomized controlled trials and meta-analysis. Pituitary 2011;14:259-265.

  39. Sarno AD, Landi ML, Cappabianca P, Di Salle F, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001;86:5256-5261.

  40. Velázquez-Chávez FJ, Tapia-González MA, González-Bárcena D. Utilidad de la cabergolina en pacientes portadores de prolactinoma resistentes o intolerantes a bromocriptina. Cir Ciruj 2009;77:173-177.

  41. Long MA, Colquhoun IR. Case report: multiple intra-cranial metastases from a prolactin-secreting pituitary tumour. Clin Radiol 1994:49;356-358.

  42. Scheithauer BW, Randall RV, Laws Jr ER, Kovacs KT, et al. Prolactin cell carcinoma of the pituitary. Clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases. Cancer 1985:55;598-604.

  43. Hurel SJ, Harris PE, McNicol AM, Foster S, et al. Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 1997;82:2962-2965.

  44. Popovic EA, Vattuone JR, Siu KH, Busmanis I, et al. Malignant prolactinomas. Neurosurgery 1991;29:127-130.

  45. Molitch ME. The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab 2008;93:4643-4645.

  46. Colao A, Di Sarno A, Landi ML, Scavuzzo F, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85:2247-2252.

  47. Ono M, Miki N, Kawamata T, Makino R, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008;93:4721- 4727.

  48. Kars M, Roelfsema F, Romijn JA, Pereira AM. Malignant prolactinoma: case report and review of the Literature. European Journal of Endocrinology 2006;155:523-534.

  49. Abech DMD, Pereira-Lima JFS, Leães CGS, Meurer RT, et al. Cell replication and angiogenesis in central nervous system tumors and their relationship with the expression of tissue prolactin and hyperprolactinemia. OJ Pathology 2012;2:50-57.

  50. Ciccarelli E, Razzore P, Gaia D, Todaro C, et al. Hyperprolactinaemia and prolactin binding in benign intracranial tumors. J Neurosurg 2001;45:70-74.

  51. Conner P, Fried G. Hyperprolactinemia; etiology, diagnosis and treatment alternatives. Acta Obstet Gynecol Scand 1998;77:249-62.

  52. Rigg LA, Lein A, Yen SS. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 1977;129:454-6.

  53. Faglia G. Should dopamine agonist treatment for prolactinomas be life-long? Clin Endocrinol (Oxf) 1991;34:173-4.

  54. Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol 2003;46:349-62.

  55. Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002;16:791-3.

  56. Colao A, Abs R, Barcena DG, Chanson P, et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 2008;68:66-71.

  57. Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 1979;31:363-72.

  58. Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999;44(12 Suppl):1121-6.

  59. Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary 2001;4:179-85.

  60. Biller BM, Molitch ME, Vance ML, Cannistraro KB, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338-43.

  61. Molitch ME. Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 2006;35:99-116.

  62. Karaca Z, Kelestimur F. Pregnancy and other pituitary disorders (including GH deficiency). Best Pract Res Clin Endocrinol Metab 2011;25:897-910.

  63. Bagozzi D. Medicamentos: seguridad y reacciones adversas. Organización Mundial de la Salud. 2008 Octubre (Actualizado 2013; consultado en 2013 Junio 16). Disponible en: http://www.who.int/mediacentre/factsheets/fs293/es/

  64. Norma Oficial Mexicana NOM-220-SSA1-2012, Instalación y operación de la farmacovigilancia. Publicada en el Diario Oficial, lunes 7 de enero de 2013. Disponible en: www. cofepris.gob.mx




2020     |     www.medigraphic.com